FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2746-2748 June 30, 2005 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Twelves, C. PubMed Citation

Every year in the United States, approximately 30,000 people receive the diagnosis of lymph-node–positive colon cancer (stage III); worldwide, the number approaches 200,000. The primary therapy for this condition is surgical resection, which cures 50 to 60 percent of patients with average-risk stage III disease.^1,2 During the past 15 years, sequential advances in chemotherapy after surgical resection (adjuvant chemotherapy) have had an irrefutable and substantial benefit, with the 4-year rate of overall survival approaching 80 percent.³ In this issue of the Journal, Twelves and colleagues report on the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial, in which 1987 patients . . . [Full Text of this Article]

Source Information

From the Network for Medical Communication and Research, North Potomac, Md. (C.A.); and the Mayo Clinic Cancer Center, Rochester, Minn. (D.J.S.).

This article has been cited by other articles:

• Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W.-Y., Grann, V. R., Hershman, D. L. (2006). Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly. JCO 24: 2368-2375 [Abstract] [Full Text]  
• (2005). Capecitabine as Adjuvant Therapy for Stage III Colon Cancer. JWatch Gastroenterology 2005: 4-4 [Full Text]